<DOC>
	<DOCNO>NCT01253265</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple dos LY2439821 Japanese patient rheumatoid arthritis .</brief_summary>
	<brief_title>A Study Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Ambulatory male female patient age 20 75 year Male patient : Agree use reliable method birth control study include barrier contraceptive monogamous relationship partner child bearing . Female patient : Are woman test negative pregnancy time entry base pregnancy test breast feeding . Women child bear potential must agree use reliable method birth control study . Patients body weight 40 105 kilogram ( kg ) Patients establish diagnosis Rheumatoid Arthritis ( RA ) Patients C reactive protein ( CRP ) measurement great upper limit normal erythrocyte sedimentation rate least 28 millimeter per hour ( mm/hr ) Patients treat regular use Methotrexate ( MTX ) least 12 week , stable treatment ( least 7.5 milligram per week ( mg/week ) ) least 8 week Patients give write informed consent approve Sponsor Institutional Review Board ( IRB ) govern investigational site Patients reliable willing make available duration study willing follow study procedure Patients use oral corticosteroid average daily dose &gt; 10 mg/day prednisone equivalent use variable dos oral corticosteroid within last 4 week Patients live vaccination within last 12 week , intend live vaccination course study , participate vaccine clinical study within last 12 week Patients diagnosis systemic inflammatory condition RA Patients evidence active vasculitis uveitis Patients diagnosis Felty 's syndrome Patients surgical treatment joint within last 8 week , require study Patients lymphoma , leukemia , malignancy within last 5 year except basal cell squamous epithelial carcinoma skin resect evidence metastatic disease Patients suffer serious bacterial infection within last 12 week , recent ongoing infection Patients evidence suspicion active tuberculosis ( TB ) medical history , physical examination , and/or chest radiograph documentation TB positive purify protein derivative ( PPD ) test Patients uncontrolled arterial hypertension characterize systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg Patients evidence positive hepatitis B ( HBV ) surface antigen , positive hepatitis B surface antibody , positive hepatitis B core antibody , hepatitis B DNA ( HBV DNA ) ; evidence human immunodeficiency virus ( HIV ) , evidence hepatitis B ; evidence hepatitis C Patients clinical laboratory test result entry outside normal reference range , result unacceptable deviation consider clinically significant investigator Patients serum creatinine &gt; 2.0 milligram per deciliter ( mg/dL ) Patients known hypogammaglobulinemia serum immunoglobulin ( Ig ) G ( IgG ) , IgM , IgA concentration less low limit normal Patients abnormality 12 lead electrocardiogram ( ECG ) . Patients donate blood 200 mL within past 30 day , 400 milliliter ( mL ) within past 90 day Patients currently enrol , discontinue within last 30 day , clinical trial involve label use investigational drug device , concurrently enrol type medical research judge scientifically medically compatible study . For unapproved DiseaseModifying AntiRheumatic Drug ( DMARDs ) , receive 30 day 5 fold half life prior inclusion whichever longer Patients previously complete withdrawn study study investigate LY2439821 Patients treat biologic DMARD currently previously 5 half live Patients serious reaction biologic DiseaseModifying AntiRheumatic Drug ( DMARDs ) Patients receive non biologics DMARDs ( MTX , sulfasalazine , bucillamine hydroxychloroquine )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>